Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

CRISPR Therapeutics AG. (11/21/18). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
  Group Piper Jaffray (Group)
Products Product Piper Jaffray Annual Healthcare Conference 2018 New York
  Product 2 Barclays Gene Editing & Gene Therapy Summit 2018 New York
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Paganelli, Jennifer (W2O Group 201703)
     


CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to participate in the following investor conferences in November:

30th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2018
Fireside Chat: 10:30 AM ET
Location: New York, NY

Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 29, 2018
Presentation: 4:00 PM ET
Panel Discussion: 4:30 PM ETFocus on Gene Editing
Location: New York, NY

A live webcast of the Piper Jaffray fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.


CRISPR Investor Contact:

Susan Kim
susan.kim@crisprtx.com


CRISPR Media Contact:

Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com

   
Record changed: 2019-01-06

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top